Mylan Strikes €642m Deal For Aspen’s Thrombosis Business In Europe
Diversifies Mylan Further Ahead Of Viatris
With Mylan continuing to count down the days until its merger with Pfizer’s Upjohn completes, the US firm has struck a deal to acquire Aspen Pharmacare’s thrombosis business in Europe, bolstering what is already a $4bn operation.
